Serum lipid profile on admission for ischemic stroke - Failure to meet national cholesterol education program adult treatment panel (NCEP-ATPIII) guidelines

被引:25
作者
Smith, Eric E.
Abdullah, Abdul R.
Amirfarzan, Houman
Schwamm, Lee H.
机构
[1] Massachusetts Gen Hosp, Stroke Serv, Boston, MA 02114 USA
[2] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA
关键词
D O I
10.1212/01.wnl.0000255941.03761.dc
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: To determine the characteristics of patients with stroke/TIA whose admission low-density lipoprotein (LDL) levels were above goals defined by National Cholesterol Education Program Adult Treatment Panel (NCEP-ATPIII) guidelines. Methods: From January 1, 2003, to June 30, 2005, there were 1,212 discharges (1,033 stroke, 179 TIA), of whom 1,040/1,212 (86%) had lipid measurement. The preadmission individual LDL goal was determined using 2001 NCEP-ATPIII guidelines. Results: There were 284/1,040 (27%) whose measured LDL was greater than the individual preadmission LDL goal. Failure to be at goal was common even among those with previously diagnosed dyslipidemia (159/527, 30%) and those taking lipid- lowering agents (LLA) (71/370, 19%). LLA would have been indicated in 121/213 (57%) of those above LDL goal who were not already taking LLA, with optional consideration in 77/213 (36%). Lower LDL therapeutic targets were the strongest predictor, in a multivariable model, of failure to be at goal. Compared to LDL target < 160 (reference), the OR for LDL target < 130 was 6.4 (95% CI 3.4 to 12.0, p < 0.0001) and for LDL target < 100 was 26.2 (95% CI 13.3 to 51.5, p < 0.0001). An increased likelihood of being at goal was associated with preadmission LLA (OR 4.2, 95% CI 2.9 to 6.2, p < 0.0001) and increasing calendar time (OR 1.09 per 3-month period, 95% CI 1.03 to 1.15, p = 0.004). Conclusions: Many patients hospitalized with ischemic stroke/TIA, including those with known dyslipidemia and those taking lipid lowering agents, have measured low-density lipoprotein (LDL) that is higher than recommended by national guidelines. Patients at the greatest risk of cardiovascular events are the least likely to be at guideline-recommended LDL levels.
引用
收藏
页码:660 / 665
页数:6
相关论文
共 32 条
  • [1] Amarenco P, 2006, NEW ENGL J MED, V355, P549
  • [2] Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins
    Baigent, C
    Keech, A
    Kearney, PM
    Blackwell, L
    Buck, G
    Pollicino, C
    Kirby, A
    Sourjina, T
    Peto, R
    Collins, R
    Simes, J
    [J]. LANCET, 2005, 366 (9493) : 1267 - 1278
  • [3] Why do patients with atrial fibrillation not receive warfarin?
    Bungard, TJ
    Ghali, WA
    Teo, KK
    McAlister, FA
    Tsuyuki, RT
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (01) : 41 - 46
  • [4] Intensive versus moderate lipid lowering with statins after acute coronary syndromes
    Cannon, CP
    Braunwald, E
    McCabe, CH
    Rader, DJ
    Rouleau, JL
    Belder, R
    Joyal, SV
    Hill, KA
    Pfeffer, MA
    Skene, AM
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (15) : 1495 - 1504
  • [5] Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
    Chobanian, AV
    Bakris, GL
    Black, HR
    Cushman, WC
    Green, LA
    Izzo, JL
    Jones, DW
    Materson, BJ
    Oparil, S
    Wright, JT
    Roccella, EJ
    [J]. HYPERTENSION, 2003, 42 (06) : 1206 - 1252
  • [6] Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
    Cleeman, JI
    Grundy, SM
    Becker, D
    Clark, LT
    Cooper, RS
    Denke, MA
    Howard, WJ
    Hunninghake, DB
    Illingworth, DR
    Luepker, RV
    McBride, P
    McKenney, JM
    Pasternak, RC
    Stone, NJ
    Van Horn, L
    Brewer, HB
    Ernst, ND
    Gordon, D
    Levy, D
    Rifkind, B
    Rossouw, JE
    Savage, P
    Haffner, SM
    Orloff, DG
    Proschan, MA
    Schwartz, JS
    Sempos, CT
    Shero, ST
    Murray, EZ
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19): : 2486 - 2497
  • [7] Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3
  • [8] Committee on quality of health care in America-Institute of Medicine, 2001, CROSS QUAL CHASM NEW
  • [9] COURNOT M, 2005, INT J CARDIOL
  • [10] Results of the National Cholesterol Education (NCEP) Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations
    Davidson, MH
    Maki, KC
    Pearson, TA
    Pasternak, RC
    Deedwania, PC
    McKenney, JM
    Fonarow, GC
    Maron, DJ
    Ansell, BJ
    Clark, LT
    Ballantyne, CM
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2005, 96 (04) : 556 - 563